A Phase II clinical trial targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial

Trial Profile

A Phase II clinical trial targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Fasoracetam (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 Patient screening is anticipated to begin in the third quarter of 2017, according to an Aevi Genomic media release.
    • 18 May 2017 New trial record
    • 10 May 2017 This trial is expected to begin in the second half of 2017 and top-line results are expected in mid-2018, according to an Aevi Genomic media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top